Pembrolizumab for advanced melanoma: experience from the Spanish Expanded Access Program

被引：0

作者：

M. González-Cao

A. Arance

J. M. Piulats

I. Marquez-Rodas

J. L. Manzano

A. Berrocal

G. Crespo

D. Rodriguez

E. Perez-Ruiz

M. Berciano

A. Soria

A. G. Castano

E. Espinosa

C. Montagut

L. Alonso

T. Puertolas

C. Aguado

M. A. Royo

R. Blanco

J. F. Rodríguez

E. Muñoz

P. Mut

F. Barron

S. Martin-Algarra

机构：

[1] Quiron Dexeus University Hospital,Translational Cancer Research Unit, Dr. Rosell Oncology Institute

[2] Hospital Clinic I Provincial,undefined

[3] Catalan Institute of Oncology,undefined

[4] Gregorio Marañón Institute of Health Research,undefined

[5] Germans Trias I Pujol University Hospital,undefined

[6] General University Hospital,undefined

[7] Burgos University Hospital,undefined

[8] Insular University Hospital of Gran Canaria,undefined

[9] Costa del Sol Hospital,undefined

[10] Regional University Hospital of Malaga,undefined

[11] Ramony Cajal Hospital,undefined

[12] Marqués de Valdecilla University Hospital,undefined

[13] La Paz University Hospital,undefined

[14] Del Mar University Hospital,undefined

[15] Virgen de la Victoria Hospital,undefined

[16] Miguel Servet University Hospital,undefined

[17] San Carlos Hospital,undefined

[18] Dr. Peset Hospital,undefined

[19] Consorci Sanitari de Terrassa,undefined

[20] Clara Campal Hospital,undefined

[21] Valld’Hebron University Hospital,undefined

[22] Son Llatzer University Hospital,undefined

[23] National Cancer Institute,undefined

[24] Navarra University Clinic,undefined

来源：

Clinical and Translational Oncology | 2017年 / 19卷

关键词：

Expanded access program; Melanoma; Pembrolizumab; Survival; CNS metastases;

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：761 / 768

页数：7

共 50 条

[21] Ipilimumab in patients with melanoma brain metastases, a single-center experience in an expanded access program
Du Four, Stephanie
Wilgenhof, Sofie
Seghers, Amelie Clementine
Duerinck, Johnny
Neyns, Bart
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
[22] IPILIMUMAB IN PATIENTS WITH MELANOMA BRAIN METASTASES, A SINGLE-CENTER EXPERIENCE IN AN EXPANDED ACCESS PROGRAM
Du Four, S.
Wilgenhof, S.
Neyns, B.
NEURO-ONCOLOGY, 2012, 14 : 79 - 79
[23] Ipilimumab in the real world: The UK expanded access programme (EAP) experience in advanced melanoma.
Ahmad, Saif
Qian, Wendi
Ellis, Sarah Gabrielle
Khattak, Muhammad Adnan
Gupta, Avinash
Thillai, Kiruthikah
Board, Ruth E.
Nobes, Jenny
Dalgleish, Angus
Grumett, Simon Aird
Maraveyas, Anthony
Danson, Sarah
Talbot, Toby
Marples, Maria
Plummer, Ruth
Kumar, Satish
Middleton, Mark R.
Larkin, James M. G.
Ottensmeier, Christian
Corrie, Philippa
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[24] Prediction of Pembrolizumab Efficacy in Non-Small-Cell Lung Cancer (NSCLC) Based on Experience From Expanded Access Program in Poland
Knetki-Wroblewska, M.
Kowalski, D. M.
Pluzanski, A.
Stanowska, O.
Wisniewski, P.
Winiarczyk, K.
Zaborowska-Szmit, M.
Zajda, K.
Prochorec-Sobieszek, M.
Krzakowski, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S641 - S641
[25] SAFETY DATA FROM AN EXPANDED ACCESS PROGRAM (EAP) OF NIVOLUMAB (NIVO) IN COMBINATION WITH IPILIMUMAB (IPI) IN PATIENTS WITH ADVANCED MELANOMA (MEL)
Chapman, Paul B.
Sznol, Mario
Lao, Christopher D.
Gonzalez, Rene
Daniels, Gregory A.
Thompson, John A.
Kudchadkar, Ragini R.
Sharfman, William H.
Atkins, Michael B.
Pavlick, Anna C.
Infante, Jeffrey R.
Kim, Kevin B.
Weber, Jeffrey S.
Nair, Suresh
Cowey, Lance
Lipson, Evan J.
Lee, Sue
Avila, Alexandre
Hodi, Stephen
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2016, 12 : 119 - 119
[26] Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL).
Chapman, Paul B.
Sznol, Mario
Lao, Christopher
Gonzalez, Rene
Daniels, Gregory A.
Thompson, John A.
Kudchadkar, Ragini Reiney
Sharfman, William Howard
Atkins, Michael B.
Pavlick, Anna C.
Infante, Jeffrey R.
Kim, Kevin
Weber, Jeffrey S.
Patel, Sapna Pradyuman
Nair, Suresh
Cowey, C. Lance
Lipson, Evan J.
Lee, Sue
Avila, Alexandre
Hodi, F. Stephen
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[27] Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
Anna Maria Di Giacomo
Riccardo Danielli
Luana Calabrò
Erica Bertocci
Chiara Nannicini
Diana Giannarelli
Angelo Balestrazzi
Francesco Vigni
Valentina Riversi
Clelia Miracco
Maurizio Biagioli
Maresa Altomonte
Michele Maio
Cancer Immunology, Immunotherapy, 2011, 60 : 467 - 477
[28] Efavirenz expanded access program: North American experience
Manion, DJ
Koziak, KZ
Block, DS
Montgomery, WC
Joseph, JL
Bessen, LJ
AIDS, 2000, 14 : S23 - S23
[29] Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
Di Giacomo, Anna Maria
Danielli, Riccardo
Calabro, Luana
Bertocci, Erica
Nannicini, Chiara
Giannarelli, Diana
Balestrazzi, Angelo
Vigni, Francesco
Riversi, Valentina
Miracco, Clelia
Biagioli, Maurizio
Altomonte, Maresa
Maio, Michele
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2011, 60 (04) : 467 - 477
[30] Ipilimumab in the real world: the UK expanded access programme experience in previously treated advanced melanoma patients
Ahmad, Saif S.
Qian, Wendi
Ellis, Sarah
Mason, Elaine
Khattak, Muhammad A.
Gupta, Avinash
Shaw, Heather
Quinton, Amy
Kovarikova, Jarmila
Thillai, Kiruthikah
Rao, Ankit
Board, Ruth
Nobes, Jenny
Dalgleish, Angus
Grumett, Simon
Maraveyas, Anthony
Danson, Sarah
Talbot, Toby
Harries, Mark
Marples, Maria
Plummer, Ruth
Kumar, Satish
Nathan, Paul
Middleton, Mark R.
Larkin, James
Lorigan, Paul
Wheater, Matthew
Ottensmeier, Christian H.
Corrie, Pippa G.
MELANOMA RESEARCH, 2015, 25 (05) : 432 - 442

← 1 2 3 4 5 →